(Hypertension. 2000;36:648.)
© 2000 American Heart Association, Inc.
Colin Johnston - A Celebration |
From the Department of Physiology, Monash University, Melbourne, Australia.
Correspondence to Prof W.P. Anderson, Department of Physiology, PO Box 13F, Monash University, Victoria 3800, Australia. E-mail warwick.anderson{at}med.monash.edu.au
| Abstract |
|---|
|
|
|---|
Key Words: angiotensin II arterioles glomerular filtration rate rats, spontaneously hypertensive renal artery hypertrophy hypertension, renal
| Introduction |
|---|
|
|
|---|
The main argument in recent years for the importance of the kidney in hypertension has come from Hall et al,4 Guyton,5 and Cowley.6 This work is widely accepted as showing the pivotal role of the arterial pressure/Na+ excretion rate relation in long-term blood pressure control. However, the mechanisms responsible for shifting this relation toward the rightthat is, toward a prohypertensive situation in humansremain unknown. In this article, we argue that primary changes in the structure of the preglomerular vessel walls may be one key mechanism responsible for a right shift of the pressure/Na+ excretion relation in hypertension.4 5 6 Using the simple situation of main renal artery stenosis as a background, we examined evidence for structurally based narrowing of the preglomerular vasculature as a possible underlying initiating cause of hypertension rather than as a secondary reaction to the hypertension in some situations.
| Prohypertensive Hemodynamics of Main Renal Artery Stenosis |
|---|
|
|
|---|
|
These measurements were made in the acute phase of production of renal stenosis. However, measurements made in longer-term steady-state renal artery stenosis show that there is increased vascular resistance of the stenotic kidney. This measured resistance is attributable almost entirely to the stenosis itself. In dogs, we measured pressure distal to the stenosis and documented both the resistance of the stenosis and the downstream vasculature.8 9 10 11 12 We found that the stenosis itself increased the resistance of the kidney by up to 50% in marked, sustained hypertension. Indeed, the stenosis resistance accounted for almost all the increase in total renal vascular resistance, whereas the renal resistance of the entire renal vasculature downstream to the stenosis was not significantly different from values measured before the induction of the stenosis.8 9 10 11 12 In stable renal artery stenosis, even when the hypertension is significant, pressure in the distal renal artery beyond the stenosis may be near normal.8 9 10 11 12 Furthermore, when glomerular capillary pressure itself has been measured (estimated from stop-flow pressure), it has been found to be normal,13 as is glomerular filtration rate (GFR).11 12
As a corollary, stenoses that are not severe enough to
increase renal vascular resistance do not cause
hypertension.11 The resistance to blood flow of a
narrowing of
70% of the lumen diameter exerts little resistance to
blood flow.11 Even greater degrees of narrowing may not
produce hypertension, in part because the renin-angiotensin
system acts intrarenally to minimize the
physiological effects of the
stenosis.9 11 Although such a stenosis may
initially lower pressure distally during acute induction experimentally
(rather than a slow progressive event as in humans), intrarenal events
occur that result in a marked lessening of the
hemodynamic effects of the stenosis. These
events appear to be mediated by angiotensin (Ang)
IIinduced vasoconstriction, which restores pressure distal to the
stenosis, which in turn reduces the hemodynamic
severity of the stenosis itself.11
When we induced very severe renal artery narrowing to more than double the resistance of the narrowed main renal artery, blood pressure below the stenosis remained low and malignant hypertension developed without restoring blood pressure distal to the stenosis toward prestenosis levels.7
Thus, increased vascular resistance characterizes main renal artery stenosis, resulting in increased aortic-glomerular capillary pressure difference. The extent of hypertension directly related to the extent of increase in this resistance. Renal artery stenosis hypertension is a simple model whose initiating event is purely renovascular. Is there evidence for other renal vascular changes that might mimic the hemodynamic effects of main renal artery stenosis and thereby cause hypertension? Goldblatt14 himself suggested that this might be the case.
| Spontaneously Hypertensive Rats |
|---|
|
|
|---|
Surprisingly, there has been relatively little study of the functional consequences of these structural changes in the vasculature of the kidney in the SHR. Studies are needed to confirm that in vivo, with the operation of all the normal control mechanisms, the renal preglomerular vessels act in a similar hemodynamic manner to main renal artery stenosis. However, there is considerable evidence that suggests this, including measurements of increased preglomerular resistance and normal blood flow and increased aortic-glomerular capillary pressure gradient.21 It would further be expected that the structural changes would augment the responses to circulating or local vasoconstrictors,22 thereby acting as an additional hypertensive stimulus by further increasing the aorta-Pgc gradientequivalent to further tightening of a main renal artery stenosis.7
We have shown that renal arterial wall hypertrophy in the SHR does not appear to be reversed by antihypertensive treatment. We studied the effects of treating SHR from weaning until 10 weeks of age with either an ACE inhibitor18 or an angiotensin (AT)1 antagonist.23 Neither agent reduced the extent of wall hypertrophy, measured by careful stereological techniques. Previously, Smeda and colleagues24 had also shown that successful treatment of the SHR hypertension with hydralazine likewise had no significant effect on preglomerular arterial wall hypertrophy. In contrast, in other vascular beds, antihypertensive treatment of the SHR does reverse the hypertrophy of arterial vessel walls.25 It is therefore interesting to speculate whether the hypertrophy of the renal vasculature is under different cellular control mechanisms and whether its development is the primary stimulus to SHR hypertension by progressively increasing the aorta-glomerular capillary pressure gradient.
It should be noted, however, that in contrast to the wall hypertrophy, Notoya et al26 and Bergstrom et al27 have shown that the remodeling of renal afferent arterioles is reversed by long-term ACE inhibition.
The presence of structural changes in preglomerular arteries and afferent arterioles before the development of hypertension and the persistence of these structural changes despite normalization of arterial pressure (with antihypertensive treatment) strongly suggest that these changes are not due to elevated arterial pressure but may instead be involved in the pathogenesis of hypertension. Consistent with this hypothesis, Norrelund et al28 found a correlation between lumen diameter of the afferent arteriole at 7 weeks of age in an F2-generation SHR/Wistar-Kyoto cross and the extent of subsequent development of hypertension.
Thus, structural changes in the preglomerular vessel wall in the SHR, whether primary or secondary to the hypertension, may mimic hemodynamically main renal artery stenosis. If there is hypertrophy and lumen reduction in the SHR, is there any evidence for this in human essential hypertension?
| Human Hypertension |
|---|
|
|
|---|
| Ang IIMediated Renal Hypertension |
|---|
|
|
|---|
We have infused Ang II at low doses directly into the renal artery for up to 1 month in both Sprague-Dawley rats35 and greyhound dogs.36 37 The doses used cause no immediate changes in arterial pressure and were doses at which little spillover into the systemic circulation would be expected (confirmed in rats).35 In rats, Ang II infused into the right renal artery (0.5, 1.5, or 4.5 ng/kg per minute) for 14 or 25 days produced dose-related increases in arterial pressure.35 The hypertension occurred whether or not the left kidney was nephectomized before or at the time of commencement of the Ang II infusion, but the extent of the hypertension was reduced by approximately one third when the left kidney was not removed but instead remained in situ. In dogs, infusion of Ang II at 0.5 ng/kg per minute produced a stable, long-lasting hypertension36 37 that was due to an increase in total peripheral resistance, as is also the case in the hypertension from renal artery stenosis. Despite the known effects of Ang II on renal Na+ handling, there was no evidence for marked salt and water retention, and the hypertension was not cardiac-output mediated.36 During the long-term Ang II infusion, renal blood flow and GFR were normal, but renal vascular resistance was elevated.36 37
We have also conducted preliminary studies on whether the long-term Ang II infusion had caused structural changes in the preglomerular resistance vessels by using the established in vitro assay of renal vessel structural changes developed by Gothberg et al.19 We have modified the technique and used it recently to study the effects of long-term ACE inhibition27 and of renal denervation in the developing SHR.38 In brief, kidneys are perfused at increasing pressure with an isotonic colloid perfuse, at maximal vasodilation, to produce pressure-flow and pressure-GFR relations, with changes in the slope and position of these relations taken to reflect structural changes in the vasculature.
We concluded from these experiments that the long-term Ang II
infusions had caused structurally based increases in renal resistance
(reduced lumen diameter; exemplified by reduced slope of the
pressure-flow relationship), caused by an apparent increased pre to
postglomerular resistance ratio (right shift of the
pressure-GFR relation).35 That is, the results indicated
that 25 days of Ang II infusion into the renal artery in rats had
produced structural remodeling of the preglomerular
vessels. In these experiments, the reduced preglomerular
lumen diameter is demonstrated most directly by comparing, during the
progressive increase in perfusion pressure in each kidney, the lowest
perfusion pressure at which the oncotic pressure of the artificial
plasma was overcome and ultrafiltration commenced.35 As
can be seen from Figure 2, this pressure
was
55 mm Hg in the vehicle rats (as expected) but was
progressively higher in the kidneys of rats that had received
increasing doses of Ang II infusion for the previous 25 days,
indicating dose-related reductions in preglomerular
resistance vessel diameter.35 Confirmation of these
findings by stereological techniques (see Reference
18 ) is under way. At this time, we cannot say whether
this is due to the direct effects of Ang II or is secondary to the
hypertension.
|
| Conclusions |
|---|
|
|
|---|
| Acknowledgments |
|---|
Received August 2, 2000; first decision August 2, 2000; accepted August 17, 2000.
| References |
|---|
|
|
|---|
2. Folkow B. Kidneys and primary hypertension: initiators, stabilizers or/and victim-aggravators? Blood Press. 1994;3:212215.[Medline] [Order article via Infotrieve]
3. Ruilope LM. How much does the kidney participate in the origin of primary hypertension? Blood Press. 1994;3:216218.[Medline] [Order article via Infotrieve]
4. Hall JE, Mizelle HL, Woods LL. The renin-angiotensin system and long-term regulation of arterial pressure. J Hypertens. 1986;4:387397.[Medline] [Order article via Infotrieve]
5.
Guyton AC. Long-term arterial
pressure control: an analysis from animal experiments and
computer and graphic models. Am J Physiol. 1990;259:R865R877.
6.
Cowley AW Jr. Role of the renal medulla in
volume and arterial pressure regulation. Am J
Physiol. 1997;273:R1R15.
7. Anderson WP, Korner P, Angus J, Johnston C. Contribution of stenosis resistance to the rise in total peripheral resistance during experimental renal hypertension in conscious dogs. Clin Sci. 1981;61:663670.[Medline] [Order article via Infotrieve]
8. Anderson WP, Selig SE, Korner PI. Role of angiotensin II in the hypertension induced by renal artery stenosis. Clin Exp Hypertens [A]. 1984;6:299314.[Medline] [Order article via Infotrieve]
9.
Anderson WP, Korner PI, Johnston CI. Acute
angiotensin II-mediated restoration of distal renal artery
pressure in renal artery stenosis and its relationship to the
development of sustained one-kidney hypertension in conscious dogs.
Hypertension. 1979;1:292298.
10.
Anderson WP, Ramsey DE, Takata M. Development of
hypertension from unilateral renal artery stenosis in conscious
dogs. Hypertension. 1990;16:441451.
11. Anderson WP, Woods RL. Intrarenal effects of angiotensin II in renal artery stenosis. Kidney Int. 1987;31:157167.
12.
Woods RL, Anderson WP, Korner PI. Renal and
systemic effects of enalapril in chronic one-kidney hypertension.
Hypertension. 1986;8:109116.
13. Schwietzer G, Gertz KH. Single-nephron hemodynamics in one-kidney one-clip hypertension in the rat. Ren Physiol. 1984;7:4653.[Medline] [Order article via Infotrieve]
14.
Goldblatt H. The renal origin of hypertension.
Physiol Rev. 1947;27:120162.
15. Harrap SB, Nicolaci JA, Doyle AE. Persistent effects on blood pressure and renal haemodynamics following chronic angiotensin converting enzyme inhibition with perindopril. Clin Exp Pharmacol Physiol. 1986;13:753765.[Medline] [Order article via Infotrieve]
16. Dilley JR, Stier CT, Arendshorst WJ. Abnormalities in glomerular function in rats developing spontaneous hypertension. Am J Physiol. 1984;246:F12F20.
17.
Smeda JS, Lee RM, Forrest JB. Structural and
reactivity alterations of the renal vasculature of spontaneously
hypertensive rats prior to and during established hypertension.
Circ Res. 1988;63:518533.
18.
Kett MM, Alcorn D, Bertram JF, Anderson WP.
Enalapril does not prevent renal arterial
hypertrophy in spontaneously hypertensive rats.
Hypertension. 1995;25:335342.
19. Gothberg G, Lundin S, Ricksten SE, Folkow B. Apparent and true vascular resistances to flow in SHR and NCR kidneys as related to the pre/postglomerular resistance ratio. Acta Physiol Scand. 1979;105:282294.[Medline] [Order article via Infotrieve]
20.
Skov K, Mulvany MJ, Korsgaard N. Morphology of
renal afferent arterioles in spontaneously hypertensive rats.
Hypertension. 1992;20:821827.
21.
Arendshorst WJ, Beierwaltes WH. Renal and nephron
hemodynamics in spontaneously hypertensive rats.
Am J Physiol. 1979;236:F246F251.
22. Korner PI, Angus JA. Structural determinants of vascular resistance properties in hypertension: haemodynamic and model analysis [published erratum appears in J Vasc Res.. 1995;32:119]. J Vasc Res. 1992;29:293312.
23. Anderson WP, Kett MM, Alcorn D, Bertram JF. Angiotensin II antagonism and pre-glomerular arterial wall dimensions in the kidney of the spontaneously hypertensive rat. Clin Exp Hypertens. 1997;19:965979.
24.
Smeda JS, Lee RM, Forrest JB. Prenatal and
postnatal hydralazine treatment does not prevent renal vessel
wall thickening in SHR despite the absence of hypertension. Circ
Res. 1988;63:534542.
25.
Lee RM, Berecek KH, Tsoporis J, McKenzie R,
Triggle CR. Prevention of hypertension and vascular changes by
captopril treatment. Hypertension. 1991;17:141150.
26.
Notoya M, Nakamura M, Mizojiri K. Effects of
lisinopril on the structure of renal arterioles.
Hypertension. 1996;27:364370.
27.
Bergstrom G, Johansson I, Stevenson KM, Kett MM,
Anderson WP. Perindopril treatment affects both
preglomerular renal vascular lumen dimensions and in vivo
responsiveness to vasoconstrictors in spontaneously hypertensive rats.
Hypertension. 1998;31:10071013.
28.
Norrelund H, Christensen KL, Samani NJ, Kimber P,
Mulvany MJ, Korsgaard N. Early narrowed afferent arteriole is a
contributor to the development of hypertension.
Hypertension. 1994;24:301308.
29.
Ruilope LM, Lahera V, Rodicio JL, Carlos Romero
J. Are renal hemodynamics a key factor in the
development and maintenance of arterial
hypertension in humans? Hypertension. 1994;23:39.
30. Weber KT, Swamynathan SK, Guntaka RV, Sun Y. Angiotensin II and extracellular matrix homeostasis. Int J Biochem Cell Biol. 1999;31:395403.[Medline] [Order article via Infotrieve]
31.
Hershey JC, Hautmann M, Thompson MM, Rothblum LI,
Haystead TA, Owens GK. Angiotensin II-induced
hypertrophy of rat vascular smooth muscle is associated
with increased 18 S rRNA synthesis and phosphorylation
of the rRNA transcription factor, upstream binding factor. J
Biol Chem. 1995;270:2509625101.
32. Anderson WP, Woods RL, Denton KM, Alcorn D. Renal actions of angiotensin II in renovascular hypertension. Can J Physiol Pharmacol. 1987;65:15591565.[Medline] [Order article via Infotrieve]
33.
Fisher ND, Allan DR, Gaboury CL, Hollenberg NK.
Intrarenal angiotensin II formation in humans: evidence
from renin inhibition. Hypertension. 1995;25:935939.
34. Webb DJ, Cumming AM, Adams FC, Hodsman GP, Leckie BJ, Lever AF, Morton JJ, Murray GD, Robertson JI. Changes in active and inactive renin and in angiotensin II across the kidney in essential hypertension and renal artery stenosis. J Hypertens. 1984;2:605614.[Medline] [Order article via Infotrieve]
35. Stevenson KM, Edgely AJ, Bergstrom G, Worthy K, Kett MM, Anderson WP. Angiotensin II infused intrarenally causes preglomerular vascular changes and hypertension. Hypertension. 2000. Submitted.
36.
Fitzgerald SM, Stevenson KM, Evans RG, Anderson
WP. Systemic hemodynamic responses to chronic
angiotensin II infusion into the renal artery of dogs.
Am J Physiol. 1997;273:R1980R1989.
37. Fitzgerald SM, Stevenson KM, Evans RG, Anderson WP. Low dose angiotensin II infusions into the renal artery induce chronic hypertension in conscious dogs. Blood Press. 1997;6:5261.[Medline] [Order article via Infotrieve]
38. Tomoda F, Bergstrom G, Evans RG, Anderson WP. Evidence for decreased structurally determined preglomerular resistance in the young spontaneously hypertensive rat after 4 weeks of renal denervation. J Hypertens. 1997;15:11871195.[Medline] [Order article via Infotrieve]
39.
Esler M, Jennings G, Korner P. Assessment of
human sympathetic nervous system activity from measurements of
norepinephrine turnover. Hypertension. 1988;11:320.
This article has been cited by other articles:
![]() |
G. Liew, J. J. Wang, P. Mitchell, and T. Y. Wong Retinal Vascular Imaging: A New Tool in Microvascular Disease Research Circ Cardiovasc Imaging, September 1, 2008; 1(2): 156 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Guan, D. A. Osmond, and E. W. Inscho Purinoceptors in the Kidney Experimental Biology and Medicine, June 1, 2007; 232(6): 715 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Imig Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases Am J Physiol Renal Physiol, September 1, 2005; 289(3): F496 - F503. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Johnson, B. Rodriguez-Iturbe, T. Nakagawa, D.-H. Kang, D. I. Feig, and J. Herrera-Acosta Subtle Renal Injury Is Likely a Common Mechanism for Salt-Sensitive Essential Hypertension Hypertension, March 1, 2005; 45(3): 326 - 330. [Full Text] [PDF] |
||||
![]() |
X. Zhao, D. M. Pollock, E. W. Inscho, D. C. Zeldin, and J. D. Imig Decreased Renal Cytochrome P450 2C Enzymes and Impaired Vasodilation Are Associated With Angiotensin Salt-Sensitive Hypertension Hypertension, March 1, 2003; 41(3): 709 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Edgley, N. R. Nichols, and W. P. Anderson Acute intrarenal infusion of ANG II does not stimulate immediate early gene expression in the kidney Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2002; 282(4): R1133 - R1139. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Johnson, J. Herrera-Acosta, G. F. Schreiner, and B. Rodriguez-Iturbe Subtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension N. Engl. J. Med., March 21, 2002; 346(12): 913 - 923. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |